Coherus BioSciences

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Coherus BioSciences reports robust Q1 results and eyes market expansion

Coherus BioSciences showcased strong financial performance, product advancements, and strategic initiatives during their Q1 2023 Earnings Call, positioning them for future growth.
While facing challenges such as potential competition and pricing uncertainties, the company's strengths in product diversity, patient engagement, and commercial readiness offer a solid foundation for success.
By capitalizing on opportunities like FDA approvals, therapy combinations, and market share goals, Coherus can navigate challenges and drive innovation in the biopharmaceutical market.

Coherus BioSciences posts robust Q2 earnings, eyes market expansion

Coherus BioSciences reported strong Q2 2023 performance with net product revenues of $58.5 million.
The company aims to achieve cash flow positivity in 2024 through expense management and revenue growth.
Focus on offering low-cost alternatives like CIMERLI and expanding market share for key products.
Plans to leverage the successful launches of UDENYCA and Toripalimab for future growth opportunities.

Coherus BioSciences reports strong Q3 revenue growth and profitability focus

Coherus BioSciences showed strong revenue growth and expense management focus for profitability.
Key products like CIMERLI and UDENYCA drove revenue growth in Q3 2023.
Adjusting R&D expenses to align with revenue and focusing on profitability until mid-2024.
Analysts raised questions on pricing dynamics, profitability goals, and pipeline development plans.

Coherus BioSciences reports strong Q4 results and focuses on growth

Coherus BioSciences showcased strong Q4 results, focusing on efficiency and growth in 2024.
The company achieved FDA approvals for key products, with UDENYCA sales showing growth and LOQTORZI gaining traction.
Financials highlighted cost reductions and pipeline progress, with a cautious approach to revenue projections.
Emphasis on controlling expenses, reducing debt, and driving revenues higher while investing in key products.

Coherus BioSciences excels in Q4 2024, poised for strategic growth

Coherus BioSciences showcased robust financial performance, operational efficiency, and strategic positioning in Q4 2024. The company's focus on revenue growth, pipeline advancement, and market share expansion bodes well for future success. While facing challenges in transitioning to an oncology-focused company, Coherus is well-equipped to capitalize on opportunities for growth.

Coherus BioSciences reports strong Q1 performance and growth opportunities

Coherus BioSciences showcased strong performance and strategic initiatives in oncology, positioning itself for future growth. While facing challenges in market penetration and competition, the company's innovative products and financial management are key strengths. Opportunities lie in revenue growth from LOQTORZI sales projections and the development of CHS-114, presenting avenues for expansion and success.

Coherus Oncology reports robust Q2 performance and eyes market dominance

Coherus Oncology's Q2 2025 performance reflects strong revenue growth, promising pipeline candidates, and a solid financial position. The company's focus on developing innovative oncology treatments and pursuing strategic partnerships positions it well for future growth and market dominance. While facing challenges in clinical trial outcomes and market competition, Coherus Oncology has opportunities to expand its market reach and drive revenue growth. Overall, Coherus Oncology's proactive approach to growth, ambitious revenue targets, and commitment to innovation present a promising outlook for investors and stakeholders.

Coherus BioSciences excels in Q3 with strong oncology performance

Coherus BioSciences showcased strong financial and operational performance in Q3 2025, driven by successful execution in oncology. The company's strategic focus on key products and global clinical trials positions it well for future growth. Challenges lie in securing partnerships and balancing expenses amidst expansion efforts.

Coherus BioSciences excels in oncology focus, debt reduction, and LOQTORZI sales

Coherus BioSciences made strategic shifts towards oncology, reducing debt significantly and boosting sales of LOQTORZI. With a strong financial position and promising oncology assets, the company aims to drive growth through partnerships and innovative treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.